Skip to main content
SpringerLink
Log in

Behandlung der überaktiven Blase

  • Leserbriefe
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Chapple C, Fiala R, Gorilovsky et al. (2006) Fesoterodine in non-neurogenic voiding dysfunction results on efficacy and safety in a phase 3 trial. Eur Urol 5(Suppl): 117 (präsentiert auf dem Kongress der European Association of Urologists (EAU) 2006, Paris, Frankreich (Abstr. 379)

    Article  Google Scholar 

  2. Robinson D (2006) A randomised double-blind placebo controlled study to evaluate the efficacy of tamsulosin OCAS in the management of women with overactive bladder. Kongress der International Continence Society (ICS) 2006, Christchurch, Neuseeland, (Abstr. 93) http://www.icsoffice.org

  3. Chapple C et al. (2006) Patients treated with solifenacin exhibited greater reductions in incontinence episodes and pad use than tolerodine ER prior to a dose increase option in a randomised double-blind overactive bladder trial (the STAR study). Int Urogynecol J 17(Suppl 2): 87 (Abstr. 50)

    Google Scholar 

  4. Chapple C et al. (2006) Treatment outcomes in the STAR study for patients self selecting to remain on original dose: comparison of solifenacin 5 mg and tolterdodine ER 4 mg. Int Urogynecol J 17(Suppl 2): 88 (Abstr. 51)

    Google Scholar 

  5. Staskin DR et al. (2005) Solifenacin versus Tolterodine – a head-to-head study: Finally! But not final? Curr Urol Rep 6: 403–404

    PubMed  Google Scholar 

  6. Jonas U, Rackley RR (2006) Letters to the Editor. Eur Urol 49: 187–188

    Article  Google Scholar 

  7. Chapple C (2006) Reply to Jonas U, Rackley RR. Eur Urol 49: 188–190

    Article  Google Scholar 

  8. Andersen NV (2006) Gunnar Lose vs. Yamanouchi. Danish Med J (Ugeskrift for Laeger) 2: 168: 546

    Google Scholar 

Download references

Interessenkonflikt

Prof. Goepel war/ist medizinischer Forscher und/oder Berater für: Apogepha, Bayer Health Care, Pharmacia, Pfizer, Yamanouchi.

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Behandlung der überaktiven Blase. Urologe 46, 422–428 (2007). https://doi.org/10.1007/s00120-007-1325-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-007-1325-6

Search

Navigation